Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jactinib
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jactinib is a small molecule Janus kinase (JAK) inhibitor developed by Suzhou Zelgen Biopharmaceuticals. It primarily targets JAK1, JAK2, and JAK3, thereby modulating the JAK-STAT signaling pathway which is crucial in the pathogenesis of various inflammatory and hematologic disorders. Jactinib is being investigated for a wide range of indications, including myelofibrosis, alopecia areata, atopic dermatitis, and idiopathic pulmonary fibrosis. In clinical trials, it has demonstrated efficacy in reducing spleen volume and improving constitutional symptoms in patients with myelofibrosis. It is the first domestically developed JAK inhibitor in China to submit a New Drug Application (NDA) for the treatment of myelofibrosis.
- Other names
- jactinib hydrochloride
02
Targets
Beyond the preview
Go deeper on jactinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jactinib.